EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice

Kunihiko Takahara, Noriyuki Ouchi, Tomonobu Takikawa, Yuta Ozaki, Lixin Fang, Hiroshi Kawanishi, Minako Tatsumi, Yoshimitsu Yura iD, Katsuhiro Kato, Mikito Takefuji, Toyoaki Murohara, Koji Ohashi iD

Physiological Reports · 2025-02 · 13 (3)

DOI: 10.14814/phy2.70135 ↗

At a glance

Journal article in Physiological Reports, published online on 2025-01-30. Written by Kunihiko Takahara and 11 co-authors. Institution: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Major MEDLINE topics: Fibroblast Growth Factors, Butyrates, Ketone Bodies. Cited 4 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: Grant-in-Aid for Scientific Research A, Takeda Science Foundation (TSF), Grant-in-Aid for Scientific Research C.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Chronic kidney disease is a life‐threatening disease worldwide. PPARα is a crucial transcriptional regulator of lipid metabolism and inflammation. Here, we examine whether a novel selective PPARα modulator, pemafibrate modulates renal injury in a model of unilateral ureteral obstruction (UUO). Administration of pemafibrate to wild‐type (WT) mice led to reduction of renal dysfunction and fibrosis after UUO with accompanying increases in plasma levels of fibroblast growth factor (FGF) 21 and ketone body β‐hydroxybutyrate (BHB). Treatment of WT mice with FGF21 or BHB precursor resulted in attenuation of renal fibrotic and inflammatory responses after UUO. Treatment of proximal tubular cells with FGF21 or BHB reduced expression of epithelial–mesenchymal transition markers. These findings suggest that pemafibrate could ameliorate renal damage, at least in part, by its abilities to increase the production of FGF21 and BHB.

Subjects

MeSH terms (MEDLINE)

Fibroblast Growth FactorsButyratesKetone BodiesAnimalsMaleMice3-Hydroxybutyric AcidPPAR alphaMice, Inbred C57BLUreteral ObstructionKidneyEpithelial-Mesenchymal TransitionBenzoxazoles

Author keywords

FGF21PPARαinflammationpemafibrateβ‐hydroxybutyrate

Substances

Fibroblast Growth Factorsfibroblast growth factor 213-Hydroxybutyric AcidButyrates(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidPPAR alphaKetone BodiesBenzoxazoles

Authors and institutions

  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Molecular Medicine and Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID profiles: Yoshimitsu Yura, Koji Ohashi

Funding

  • Grant-in-Aid for Scientific Research A
  • Takeda Science Foundation (TSF)
  • Grant-in-Aid for Scientific Research C

Cite

APA

Takahara, K., Ouchi, N., Takikawa, T., Ozaki, Y., Fang, L., Kawanishi, H., Tatsumi, M., Yura, Y., Kato, K., Takefuji, M., Murohara, T., & Ohashi, K. (2025). Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice. Physiological Reports, 13(3). https://doi.org/10.14814/phy2.70135

Vancouver

Takahara K, Ouchi N, Takikawa T, Ozaki Y, Fang L, Kawanishi H, et al. Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice. Physiological Reports. 2025;13(3). doi:10.14814/phy2.70135

BibTeX
@article{Takahara2025,
  author = {Takahara, Kunihiko and Ouchi, Noriyuki and Takikawa, Tomonobu and Ozaki, Yuta and Fang, Lixin and Kawanishi, Hiroshi and Tatsumi, Minako and Yura, Yoshimitsu and Kato, Katsuhiro and Takefuji, Mikito and Murohara, Toyoaki and Ohashi, Koji},
  title = {Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice},
  journal = {Physiological Reports},
  year = {2025},
  volume = {13},
  number = {3},
  doi = {10.14814/phy2.70135}
}
Start for free →